Clinical Trial Search

Primary: Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4) — 0.04; 0.45; -0.02; 0.12 units on a scale

Primary: Change in Mean Daily Steps From Baseline Relative to Control — 6195; 6709; 7599 Mean daily steps — p=.81

Primary: Phase I: Recommended Phase II Dose (RP2D) of BYL-719 (Alpelisib) + Nab-paclitaxel to be Used in Combination to Treat Advanced HER2-negative Breast Cancer — 350 mg

Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants

Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16 — -0.57; -0.17 "mmol/L" — p=0.029

Primary: Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric…

Primary: Change From Baseline Smoking Abstinence Rates at 12 Weeks — 27; 17 Participants

Primary: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 — 12.04; 19.26 Percentage of Participants

Primary: Changes in Body Weight From Baseline — -1.88; -1.77 Kilograms

Primary: Proportion of Responders at the End of 8-week — 60.6; 36.8 percentage of participants

Primary: Plasma Pamiparib Pharmacokinetics: Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-∞) — 29300 hours*nanograms/milliLiter (h*ng/mL)

Primary: Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7 — 6.35; 13.22 units on a scale — p=0.01

Primary: Expanded Disability Status Scale Score (EDSS) — 3.0; 3.0; 2.5 EDSS Score